血清神經元烯醇化酶水平對小細胞肺癌預后影響的系統評價_《中國循證醫學雜志》

作者：

湯建華 ¹ , 張志華 ¹ ,  王睿 ² , 唐惠林 ³ , 張桂云 ² , 龍麗艷 ² , 陳良安 ²

1. 河北北方學院附屬第一醫院（張家口 000750）；2. 解放軍總醫院循證醫學中心（北京 100853）；3. 北京大學第三臨床醫學院藥劑科（北京 100191）;

關鍵詞：

神經元烯醇化酶小細胞肺癌預后系統評價

DOI：

10.7507/1672-2531.20090016

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　評價血清神經元烯醇化酶（NSE）水平對小細胞肺癌患者的預后影響。
方法　計算機檢索MEDLINE、EMbase、CBMdisc、Cochrane Central Register of Controlled Trials 等數據庫，并從符合納入標準的文獻中查找相關文獻。檢索時間從1950年到2007年12月。由2 名評價者獨立檢索、評價文獻交叉核對后提取有效數據進行Meta 分析。
結果　共納入9 個研究共2 021例小細胞肺癌患者。按作者對NSE 水平的截斷值，其中66.0%（36.5%～79%）的病例血清NSE 濃度呈現高水平。NSE濃度高水平對患者的危害是NSE 低水平的1.27倍［95%CI（1.19，1.35），P=0.281］。
結論　治療前NSE濃度高水平患者預后總生存率較NSE低水平患者差，NSE水平對小細胞肺癌預后有一定的預測價值。但由于本研究納入文獻可能存在發表偏倚、選擇偏倚、測量偏倚的高度可能性，上述結論應慎重對待。期待更多高質量、同質性的研究來精確評價NSE 的預后價值。

引用本文： 湯建華,張志華,王睿,唐惠林,張桂云,龍麗艷,陳良安. 血清神經元烯醇化酶水平對小細胞肺癌預后影響的系統評價. 中國循證醫學雜志, 2009, 09(1): 76-80. doi: 10.7507/1672-2531.20090016 復制

1.	Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin, 2000, 50: 7-33.
2.	Parkin DM, Bray F, Ferlay J, et al. Global Cancer Statistics. CA Cancer J Clin, 2005, 55: 74-108.
3.	Lassen U, Osterlind K, Hansen M, et al. Long-term survival in small-cell lung duration in small cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years. An analysis of 1, 714 consecutive patients. J Clin Oncol, 1995, 13: 1215-1220.
4.	Lassen U, Osterlind K, Hansen M, et al. Long-term survival in smallcell lung cancer: posttreatment characteristics in patients surviving 5 to 18+years. An analysis of 1, 714 consecutive patients. J Clin Oncol, 1995, 13: 1215-1220.
5.	Souhami RL, Bradbury I, Geddes DM, et al. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res, 1985, 45: 2878-2882.
6.	Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res, 1986, 46: 4189-4194.
7.	Ar r i a g ada R, Le Che v a l i e r T, Pi gnon JP, e t al . Ini t i a l chemotherapeutic doses and survival in patients with limited smallcell- lung cancer. N Engl J Med, 1993, 329: 1848-1852.
8.	Deglor igio CM, Got t PS, RobininczAL, e t al . Neuron - specificennlase, a marker of acute neuronal injury is increased in complex partial status epilepticus. Epilepsia, 1996, 37(7): 606.
9.	歷為良, 錢桂生, 黃桂君, 等. 人肺癌組織細胞Na/H交換蛋白-1基因的表達與其抗凋亡的關系. 中國癌癥雜志, 2000, 10(2): 14.
10.	馬蘭海. 血清神經元特異性烯醇化酶對小細胞肺癌的診斷價值探討. 放射免疫學雜志, 2002, 15(6): 351-352.
11.	劉關鍵, 吳泰相, 康德英. Meta-分析中的統計學過程. 中國臨床康復, 2003, 7(4): 538-539.
12.	Johnson PWM, Joel SP, Love S, et al. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer, 1993, 67: 760-766.
13.	JorgensenLGM, Osterlind K, Genolia J, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC) a combined multivariable analysis on data from nine centres. Br J Cancer, 1996, 74: 463-467.
14.	Quoix E, PurohitM A, Beau F, et al. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer, 2000, 30: 127-134.
15.	Shibayama T, Ueoka H, Nishii K, et al. Complementary roles of progastrin- releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer, 2001, 32: 61-69.
16.	金炳文, 趙蘭, 周彩存, 等. 神經元特異性烯醇化酶檢測在小細胞肺癌預后中的價值. 中華結核和呼吸雜志, 2001, 24(12): 722-724.
17.	Bremnes RM, Sundstrom S, Aaseb? U, et al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer, 2003, 39: 303-313.
18.	Ando S, Suzuki M, Yamamoto N, et al. The prognostic value of both NSE and cyfra21-1 in Small Cell Lung Cancer. Anticancer Res, 2004, 24: 1941-1946.
19.	宋麗華, 宋現讓, 張錫芹, 等. 小細胞肺癌患者預后因素分析. 中華腫瘤雜志, 2004, 26(7): 413-416.
20.	劉麗詩, 胡華成. 神經元特異性烯醇化酶、癌胚抗原、乳酸脫氫酶在小細胞肺癌中的預后價值比較. 蘇州大學學報(醫學版), 2005, 25 (2): 261-264.

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin, 2000, 50: 7-33.
2. Parkin DM, Bray F, Ferlay J, et al. Global Cancer Statistics. CA Cancer J Clin, 2005, 55: 74-108.
3. Lassen U, Osterlind K, Hansen M, et al. Long-term survival in small-cell lung duration in small cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years. An analysis of 1, 714 consecutive patients. J Clin Oncol, 1995, 13: 1215-1220.
4. Lassen U, Osterlind K, Hansen M, et al. Long-term survival in smallcell lung cancer: posttreatment characteristics in patients surviving 5 to 18+years. An analysis of 1, 714 consecutive patients. J Clin Oncol, 1995, 13: 1215-1220.
5. Souhami RL, Bradbury I, Geddes DM, et al. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res, 1985, 45: 2878-2882.
6. Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res, 1986, 46: 4189-4194.
7. Ar r i a g ada R, Le Che v a l i e r T, Pi gnon JP, e t al . Ini t i a l chemotherapeutic doses and survival in patients with limited smallcell- lung cancer. N Engl J Med, 1993, 329: 1848-1852.
8. Deglor igio CM, Got t PS, RobininczAL, e t al . Neuron - specificennlase, a marker of acute neuronal injury is increased in complex partial status epilepticus. Epilepsia, 1996, 37(7): 606.
9. 歷為良, 錢桂生, 黃桂君, 等. 人肺癌組織細胞Na/H交換蛋白-1基因的表達與其抗凋亡的關系. 中國癌癥雜志, 2000, 10(2): 14.
10. 馬蘭海. 血清神經元特異性烯醇化酶對小細胞肺癌的診斷價值探討. 放射免疫學雜志, 2002, 15(6): 351-352.
11. 劉關鍵, 吳泰相, 康德英. Meta-分析中的統計學過程. 中國臨床康復, 2003, 7(4): 538-539.
12. Johnson PWM, Joel SP, Love S, et al. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer, 1993, 67: 760-766.
13. JorgensenLGM, Osterlind K, Genolia J, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC) a combined multivariable analysis on data from nine centres. Br J Cancer, 1996, 74: 463-467.
14. Quoix E, PurohitM A, Beau F, et al. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer, 2000, 30: 127-134.
15. Shibayama T, Ueoka H, Nishii K, et al. Complementary roles of progastrin- releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer, 2001, 32: 61-69.
16. 金炳文, 趙蘭, 周彩存, 等. 神經元特異性烯醇化酶檢測在小細胞肺癌預后中的價值. 中華結核和呼吸雜志, 2001, 24(12): 722-724.
17. Bremnes RM, Sundstrom S, Aaseb? U, et al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer, 2003, 39: 303-313.
18. Ando S, Suzuki M, Yamamoto N, et al. The prognostic value of both NSE and cyfra21-1 in Small Cell Lung Cancer. Anticancer Res, 2004, 24: 1941-1946.
19. 宋麗華, 宋現讓, 張錫芹, 等. 小細胞肺癌患者預后因素分析. 中華腫瘤雜志, 2004, 26(7): 413-416.
20. 劉麗詩, 胡華成. 神經元特異性烯醇化酶、癌胚抗原、乳酸脫氫酶在小細胞肺癌中的預后價值比較. 蘇州大學學報(醫學版), 2005, 25 (2): 261-264.

上一篇
臨床病理討論——咳嗽、咳白痰、雙肺陰影
下一篇
12例重癥軍團菌肺炎回顧性分析

《中國循證醫學雜志》

血清神經元烯醇化酶水平對小細胞肺癌預后影響的系統評價

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《中國循證醫學雜志》

血清神經元烯醇化酶水平對小細胞肺癌預后影響的系統評價

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料